Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1794, Issue 10, 2009, Pages 1449-1458

  Silva, Andre M N ^a   Hider, Robert C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Albumin bound iron; Glycation; Human serum albumin; NTBI; Oxidation; Post translation modification

Indexed keywords

CITRIC ACID; HUMAN SERUM ALBUMIN; IRON DERIVATIVE; NITRILOTRIACETIC ACID; NON TRANSFERRIN BOUND IRON; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; BINDING AFFINITY; CONTROLLED STUDY; DIABETES MELLITUS; GEL FILTRATION; GLYCATION; ION TRANSPORT; IRON BINDING CAPACITY; OXIDATION; OXIDATIVE STRESS; PH; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN MODIFICATION; PROTEIN PROCESSING;

CALCIUM; CHROMATOGRAPHY, GEL; CITRIC ACID; DIABETES MELLITUS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYDROGEN-ION CONCENTRATION; IRON; IRON OVERLOAD; LIGANDS; MASS SPECTROMETRY; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SERUM ALBUMIN; SOLUTIONS; TRANSFERRIN;

EID: 69449101913     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2009.06.003     Document Type: Article

References (59)

1. McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., Hediger M.A., Hentze M.W., and Simpson R.J. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5 (2000) 299-309
2. Cazzola M., Huebers H.A., Sayers M.H., MacPhail P., Eng M., and Finch C.A. Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood 66 (1985) 935-939
3. Hershko C. Study of chelating agent diethylenetriaminepentaacetic acid using selective radioiron probes of reticuloendothelial and parenchymal iron stores. J. Lab. Clin. Med. 85 (1975) 913-921
4. Hershko C., Graham G., Bates G.H., and Rachmilewitz E.A. Non-specific serum iron in thalassemia - abnormal serum iron fraction of potential toxicity. Br. J. Hematol. 40 (1978) 255-263
5. Graham G., Bates G.W., Rachmilewitz E.A., and Hershko C. Non-specific serum iron in thalassemia - quantitation and chemical-reactivity. Am. J. Hematol. 6 (1979) 207-217
6. Aruoma O.I., Bomford A., Polson R.J., and Halliwel B. Nontransferrin-bound iron in plasma from hemochromatosis patients - effects of phlebotomy therapy. Blood 72 (1988) 1416-1419
7. Gutteridge J.M.C., Rowley D.A., Griffiths E., and Halliwel B. Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic hemochromatosis. Clin. Sci. 68 (1985) 463-467
8. Marwah S.S., Wheelwright D., Blann A.D., Rea A., Beresford R., Phillips J.D., Wright J., and Bareford D. Vitamin E correlates inversely with non-transferrin-bound iron in sickle cell disease. Br. J. Haematol. 114 (2001) 917-919
9. Bradley S.J., Gosriwatana I., Sricharairatanakool S., Hider R.C., and Porter J.B. Non-transferrin-bound iron (NTBI) induced by cytotoxic chemotherapy. Br. J. Haematol. 88 (1996) 705-713
10. Durken M., Herrnring C., Finckh B., Nagel S., Nielsen P., Fisher R., Berger H.M., Moison R.M.W., Pichlmeier U., Kohlschutter B., Zander A.R., and Kohlschutter A. Impaired plasma antioxidative defense an increase nontransferrin-bound iron during high-dose chemotherapy and radiotherapy preceding bone marrow transplantation. Free Radical Biol. Med. 28 (2000) 887-894
11. Porter J.B., Abeysinghe R.D., Marshall L., Hider R.C., and Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88 (1996) 705-713
12. Jacobs E.M.G., Hendricks J.C.M., van Tits B.L.J.H., Evans P.J., Breuer W., Liu D.Y., Jansen E.H.J.M., Jauhiainen K., Sturm B., Porter J.B., Scheiber-Mojdehkar B., Von Bonsdorff L., Cabantchik Z.I., Hider R.C., and Swinkles D.W. Results of an international round robin for the quantification of serum non-transferrin-bound iron: need for defining standardization and a clinically relevant isoform. Anal. Biochem. 341 (2005) 241-250
13. Lee D.H., Liu D.Y., Jacobs D.R., Shin H.R., Song K., Lee I.K., Kim B., and Hider R.C. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 29 (2006) 1090-1095
14. Oudit G.Y., Sun H., Trivieri M.G., Koch S.E., Dawood F., Ackerley C., Yazdanpanah M., Wilson G.J., Schwartz A., Liu P.P., Backx, and L-type Ca2+ P.H. channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nat. Med. 9 (2003) 1187-1194
15. May P.M., Linder P.W., and Williams D.R. Computer-simulation of metal-ion equilibria in biofluids - models for low-molecular-weight complex distribution of calcium(II), magnesium(II), manganese(II), iron(III), copper (II), zinc(II) and lead(II) ions in human-blood plasma. J. Chem. Soc. Dalton Trans. (1977) 588-595
16. Grootveld M., Bell J.D., Halliwell B., Aruoma O.I., Bomford A., and Sadler P.J. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis - characterization by high-performance liquid-chromatography and nuclear magnetic-resonance spectroscopy. J. Biol. Chem. 15 (1989) 4417-4422
17. Hider R.C. Nature of nontransferrin-bound iron. Eur. J. Clin. Invest. 32 (2002) 50-54
18. He X.M., and Carter D.C. Atomic-structure and chemistry of human serum-albumin. Nature 358 (1992) 209-215
19. Løvstad R.A. Interactions of serum-albumin with the Fe(III)-citrate complex. Int. J. Biochem. 25 (1993) 1015-1017
20. Loban A., Kime R., and Powers H. Iron binding antioxidant potential of plasma albumin. Clin. Sci. 93 (1997) 445-451
21. Xu X., Zhang L., Shen D., Wu H., and Liu Q. Oxygen-dependent oxidation of Fe(II) to Fe(III) and interactions of Fe(III) with bovine serum albumin, leading to a hysteretic effect on the fluorescence of bovine serum albumin. J. Fluoresc. 18 (2008) 193-201
22. Evans R.W., Rafique R., Zarea A., Rapisarda C., Cammack R., Evans P.J., Porter J.B., and Hider R.C. Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera. J. Biol. Inorg. Chem. 13 (2008) 57-74
23. Roche M., Rondeau P., Singh N.R., Tarnus E., and Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 582 (2008) 1783-1787
24. Oettl K., and Stauber R.E. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br. J. Pharmacol. 151 (2007) 580-590
25. Ramakrishna V., and Jailkhani R. Oxidative stress in non-insulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetol. 45 (2008) 41-46
26. Cighetti G., Duca L., Bortone L., Sala S., Nava I., Fiorelli G., and Cappellini M.D. Oxidative status and malondialdehyde in beta-thalassaemia. Eur. J. Clin. Invest. 32 (2002) 55-60
27. De Luca C., Filosa A., Grandinetti M., Maggio F., Lamba M., and Passi S. Blood antioxidant status and urinary levels of catecholamine metabolites in beta-thalassemia. Free Radic. Res. 30 (1999) 453-462
28. Qian M., Liu M., and Eaton J.W. Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem. Biophys. Res. Commun. 250 (1998) 385-389
29. e{open}-(carboxymethyl)hydroxylysine in human skin collagen. Biochemistry 30 (1991) 12005-12010
30. Anraku M., Tsurusaki Y., Watanabe H., Maruyama T., Kragh-Hansen U., and Otagiri M. Stabilizing mechanisms in commercial albumin preparations: octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress. Biochem. Biophys. Acta 1702 (2004) 9-17
31. Kawakami A., Kubota K., Yamada N., Tagami U., Takehada K., Sonaka I., Suzuki E., and Hirayama K. Identification and characterization of oxidized human serum albumin. A slight structural change impairs its ligand-binding and antioxidant functions. FEBS J. 273 (2006) 3346-3357
32. Habeeb A.F.S.A. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem. 14 (1966) 328-336
33. Cayot P., and Tainturier G. The quantification of protein amino groups by the trinitrobenzenesulfonic acid: a reexamination. Anal. Biochem. 249 (1997) 184-200
34. Wolff S.P. Ferrous ion oxidation in presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods Enzymol. 233 (1994) 182-189
35. Levine R.L., Williams J., Stadtman E.R., and Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233 (1994) 346-357
36. Ellman G.L. A colorimetric method for determining low concentrations mercaptans. Arch. Biochem. Biophys. 74 (1958) 443-450
37. Curry S., Mandelkow H., Brick P., and Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat. Struct. Biol. 5 (1998) 827-835
38. Pace C.N., Vajdos F., Fee L., Grimsley G., and Gray T. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4 (1995) 2411-2423
39. Stocker R., Glazer A.N., and Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5918-5922
40. Gosriwatana I., Loreal O., Lu S., Brissot P., Porter J., and Hider R.C. Quantification of non-transferrin-bound iron in the presence of unsaturated transferring. Anal. Biochem. 273 (1999) 212-220
41. Niki E. Antioxidants in relation to lipid peroxidation. Chem. Phys. Lipids 44 (1987) 227-253
42. T. Peters, All About Albumin: Biochemistry, Genetics and Medical Applications, Academic Press, Jamestown Road, London, UK, 1996.
43. Van Campenhout A., Van Campenhout C., Lagrau A.R., Moorkens G., De Block C., and Manuel-y-Keenoy B. Iron-binding antioxidant capacity is impaired in diabetes mellitus. Free Radical Biol. Med. 40 (2006) 1749-1755
44. Kisugi R., Kouzuma T., Yamamoto T., Akizuki S., Miyamoto H., Someya Y., Yokoyama J., Abe I., Hirai N., and Ohnishi A. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin. Chim. Acta 382 (2007) 59-64
45. Chakravarti B., and Chakravarti D.N. Oxidative modification of proteins: age-related changes. Gerentology 53 (2007) 128-139
46. Hinton D.J.S., and Ames J.M. Site specificity of glycation and carboxymethylation of bovine serum albumin by fructose. Amino Acids 30 (2006) 425-433
47. Banerjee D., Madhusoodanan U.K., Sharanabasappa M., Ghosh S., and Jacob J. Measurement of plasma hydroperoxide concentration by FOX-1 assay in conjunction with triphenylphosphine. Clin. Chim. Acta 337 (2003) 147-152
48. Mostafa A.A., Randell E.W., Vasdev S.C., Gill V.D., Han Y., Gadag V., Raouf A.A., and Said H.E. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol. Cell Biochem. 302 (2007) 35-42
49. Campbell A.N., and Lakshminarayanan G.R. Conductances and surface tensions of aqueous solutions of sodium decanoate, sodium laurate, and sodium myristate, at 25° and 35°. Can. J. Chem. 43 (1965) 1729-1737
50. Beers M.H., et al. The Merk Manual of Geriatrics. 3rd Ed. (2000), Merck Research Laboratories, Whitehouse Station, NJ
51. 59Fe. Biochem. Pharmacol. 16 (1967) 2033-2036
52. Van Der Heul C., Van Eijk H.G., Wiltink W.F., and Leijnse B. The binding of iron to transferrin and to other serum components at different degrees of saturation with iron. Clin. Chim. Acta 38 (1972) 347-353
53. Gautier-Luneau I., Merle C., Phanon D., Lebrun C., Biaso F., Serratrice G., and Pierre J.L. New trends in the chemistry of iron(III) citrate complexes: correlations between X-ray structures and solution species probed by electrospray mass spectrometry and kinetics of iron uptake from citrate by iron chelators. Chem. Eur. J. 11 (2005) 2207-2219
54. Niwa T. Mass spectrometry for the study of protein glycation in disease. Mass Spectrom. Rev. 25 (2006) 713-723
55. Ahmed N. Advanced glycation endproducts - role in pathology of diabetic complications. Diab. Res. Clin. Pract. 67 (2005) 3-21
56. Schmidt A.M., Hasu M., Popov D., Zhang J.H., Chen J., Yan S.D., Brett J., Cao R., Kuwabara K., Costache G., Simionescu N., Simionescu M., and Stern D. Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 8807-8811
57. Lapolla A., Piarulli F., Sartore G., Cereillo A., Ragazzi E., Reitano R., Baccarin L., Laverda B., and Fedele D. Advanced glycation end products and antioxidant status in type2 diabetic patients with and without peripheral artery disease. Diabetes Care 30 (2007) 670-676
58. Wautier M.P., Chappey O., Corda S., Stern D.M., Schmidt A.M., and Wautier J.L. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E685-E694
59. Fernandez-Real J.M., Lopez-Bermejo A., and Ricart W. Cross-talk between diabetes and iron metabolism. Diabetes 51 (2002) 2348-2354